Patients in both the first group and the second groups had a statistically positive effect on the symptoms after 10 days of in-patient treatment according to Neurological Symptom Score. In all patients before administration of the drug, after 10 days of in-hospital treatment and 2 months after treatment, clinical neurological examination was performed to evaluate neurological status, as well as dynamic examination using special clinical questionnaires (scales): Neurological Symptom Score and Total Symptom Score. Forte intramuscularly for 10 days while in hospital, then 1 capsule twice a day for 2 months. The second group (15 patients) before treatment received by group 1 was treated with Nucleo C.M.P. The first group (15 patients) received: alpha-lipoic acid at a dose of 600 mg intravenously, B vitamins: injections - for 10 days while in hospital and tablets - for one month at home. The level of glycated hemoglobin was from 7.1 to 10.4 %. Thirty patients with DM types 1 and 2 (8 men and 22 women) and DPN were examined. Forte in the comprehensive treatment of DPN. The objective was to study the effectiveness of Nucleo C.M.P. For adequate treatment of DPN, it is necessary to know that pathogenesis of neuropathy in DM is associated with overall metabolic lesion of neuronal membranes. Sometimes, DPN precedes the onset of clinical signs of DM. About 80 % of patients with DPN are asymptomatic, and the painful form of DPN is diagnosed in 10–20 % of cases. At the time of manifestation of DM, up to 6 % of patients have signs of diabetic polyneuropathy (DPN), after 5 years of the disease, they are observed in 15 %, and after 15 years - in 25 % of patients with DM. Forte Abstract Background.Diabetes mellitus (DM) is one of the socially significant diseases. Vinnytsia Regional Clinical Highly-Specialized Endocrinology Center, Vinnytsia, Ukraineĭiabetes mellitus, diabetic polyneuropathy, Nucleo C.M.P. According to the WHO, 817 clinical studies are currently conducted in Lebanon.National Pirogov Memorial Medical University, Vinnytsia, Ukraine Lebanon has 14 CROs, and is ranked as one of the largest countries in the world in clinical studies. Ixempra, a medicinal product withdrawn in Europe is imported to lebanonĪ vaccine made in India, removed from WHO list of prequalified vaccines, is submitted for registration in Lebanon Some Non-Marketed medicines are still imported The Minister of Public Health, has decided to suspend the commercialization of AB Slim (Ab Care Medical Herbs), which contains sibutramine, sildenafil and phenolphthalein The price of the most expensive medicine available in Lebanon is 30434557 LLĪt least 1309 medicinal products are more expensive in Lebanon than in the countries of originĭaktavira, a generic of Daklinza, is registered in Lebanon but has no public priceģ52 medicinal products have been declared as non-marketed or withdrawnĦ4.72% of lebanese pharmacists are femaleĤ86 medicines were submitted to the Ministry of Health for a marketing authorization, and 514 medicines were registered to date In Lebanon, 88 generic medicinal products are more expensive than their OriginatorsĪ medicinal product refused in Europe is marketed in LebanonĪt least 332 medicinal products are available on the Lebanese market and are not available in the country of origin 769 Pharmacists work as Medical Representative, of which 39 work as Senior Medical RepresentativeĢ16 non Pharmacists work as Medical Representative, and 54 work as Senior Medical Representative
0 Comments
Leave a Reply. |